The Preventive Potential of Bupropion on Aortic Aneurysm Progression: A Real-World Data Analysis
Presented During:
Thursday, April 25, 2024: 5:38PM - 7:00PM
Sheraton Times Square
Posted Room Name:
Central Park
Abstract No:
P0342
Submission Type:
Abstract Submission
Authors:
Panagiotis Tasoudis (1), Christopher Agala (2), Kyle Alexander (3), John Blackwell (4), Elizabeth Collins (3), Yiwen Ding (3), Thomas Caranasos (5), John Ikonomidis (6), Adam Akerman (3)
Institutions:
(1) University of North Carolina, Chapel Hill, NC, USA, (2) UNC Chapel Hill, Chapel Hill, NC, (3) University of North Carolina, Chapel Hill, NC, (4) UNC at Chapel Hill, Chapel Hill, NC, (5) N/A, Chapel Hill, United States, (6) UNC Medical Center, Chapel Hill, NC
Submitting Author:
Panagiotis Tasoudis
-
Contact Me
University of North Carolina
University of North Carolina
Co-Author(s):
Christopher Agala
-
Contact Me
UNC Chapel Hill
UNC Chapel Hill
Kyle Alexander
-
Contact Me
University of North Carolina
University of North Carolina
John Blackwell
-
Contact Me
UNC at Chapel Hill
UNC at Chapel Hill
Elizabeth Collins
-
Contact Me
University of North Carolina
University of North Carolina
Yiwen Ding
-
Contact Me
University of North Carolina
University of North Carolina
Thomas Caranasos
-
Contact Me
N/A
N/A
*John Ikonomidis
-
Contact Me
UNC Medical Center
UNC Medical Center
Adam Akerman
-
Contact Me
University of North Carolina
University of North Carolina
Presenting Author:
Panagiotis Tasoudis
-
Contact Me
N/A
N/A
Abstract:
Objective:
Bupropion is purported to effectively modulate two distinct pathways linked to the progression of aortic aneurysms. Notably, current literature indicates that bupropion demonstrates a capacity to inhibit the circulating levels of IL-6, MMP-2, and MMP-9, while concurrently increasing TIMP-1. This dual action aims to mitigate the advancement of aortic aneurysms. The principal objective of our study is to investigate the potential preventive impact of Bupropion on the progression of aortic aneurysms.
Methods:
Utilizing the Medicare Claims database (2007-2017), we identified a cohort of patients with major depressive disorder, seasonal affective disorder, and tobacco use-conditions for which Bupropion is FDA-approved. The comparative group included patients prescribed alternative medications (including SSRIs, SNRIs, mirtazapine, buspirone, nefazodone, trazodone, vilazodone, vortioxetine, varenicline, and nicotine) for the same diagnoses. Employing a comparative approach, we aimed to isolate the potential impact of Bupropion on aortic aneurysm progression. Throughout the study, patient aortic aneurysm development or interventions for repair were diligently tracked. The Kaplan-Meier method was employed for analysis.
Results:
In the database, we identified 916 patients treated with Bupropion and 46,052 treated with alternative medications. The median time to aneurysm diagnosis or repair was 29 months [IQR: 10, 60] in the Bupropion arm compared to 22 months [IQR: 8, 46] in the comparative arm (p<0.001).
Conclusions:
Our results generate the hypothesis that Bupropion might exhibit protective effects against aneurysm development and progression. This real-world data analysis aims to contribute valuable insights into the potential role of Bupropion in preventing the progression of aortic aneurysms, illuminating its broader cardiovascular implications beyond its well-established antidepressant properties.
Bupropion is purported to effectively modulate two distinct pathways linked to the progression of aortic aneurysms. Notably, current literature indicates that bupropion demonstrates a capacity to inhibit the circulating levels of IL-6, MMP-2, and MMP-9, while concurrently increasing TIMP-1. This dual action aims to mitigate the advancement of aortic aneurysms. The principal objective of our study is to investigate the potential preventive impact of Bupropion on the progression of aortic aneurysms.
Methods:
Utilizing the Medicare Claims database (2007-2017), we identified a cohort of patients with major depressive disorder, seasonal affective disorder, and tobacco use-conditions for which Bupropion is FDA-approved. The comparative group included patients prescribed alternative medications (including SSRIs, SNRIs, mirtazapine, buspirone, nefazodone, trazodone, vilazodone, vortioxetine, varenicline, and nicotine) for the same diagnoses. Employing a comparative approach, we aimed to isolate the potential impact of Bupropion on aortic aneurysm progression. Throughout the study, patient aortic aneurysm development or interventions for repair were diligently tracked. The Kaplan-Meier method was employed for analysis.
Results:
In the database, we identified 916 patients treated with Bupropion and 46,052 treated with alternative medications. The median time to aneurysm diagnosis or repair was 29 months [IQR: 10, 60] in the Bupropion arm compared to 22 months [IQR: 8, 46] in the comparative arm (p<0.001).
Conclusions:
Our results generate the hypothesis that Bupropion might exhibit protective effects against aneurysm development and progression. This real-world data analysis aims to contribute valuable insights into the potential role of Bupropion in preventing the progression of aortic aneurysms, illuminating its broader cardiovascular implications beyond its well-established antidepressant properties.
Aortic Symposium:
Other - Aortic aneurysm
Image or Table
